Literature DB >> 17600836

Effects of EP1 receptor on cerebral blood flow in the middle cerebral artery occlusion model of stroke in mice.

Sofiyan Saleem1, Rung-chi Li, Guo Wei, Sylvain Doré.   

Abstract

The lipid mediator prostaglandin E2 (PGE2) exhibits diverse biologic activity in a variety of tissues. Four PGE2 receptor subtypes (EP1-4) are involved in various physiologic and pathophysiologic conditions, but differ in tissue distribution, ligand-binding affinity, and coupling to intracellular signaling pathways. To characterize the role of the EP1 receptor, physiologic parameters (mean arterial blood pressure, pH, blood gases PaO2 and PaCO2, and body temperature), cerebral blood flow (CBF), and neuronal cell death were studied in a middle cerebral artery occlusion model of ischemic stroke in wild-type (WT) and EP1 knockout (EP1-/-) mice. The right middle cerebral artery was occluded for 60 min, and absolute CBF was measured by [14C] iodoantipyrine autoradiography. The effect of EP1 receptor on oxidative stress in neuronal cultures was investigated. Although no differences were observed in the physiologic parameters, CBF was significantly (P < 0.01) higher in EP1-/- mice than in WT mice, suggesting a role for this receptor in physiologic and pathophysiologic control of vascular tone. Similarly, neuronal cultures derived from EP1-/- mice were more resistant (90.6 +/- 5.8% viability) to tert-butyl hydroperoxide-induced oxidative stress than neurons from WT mice (39.6 +/- 17.2% viability). The EP1 receptor antagonist SC-51089 and calcium channel blocker verapamil each attenuated the neuronal cell death induced by PGE2. Thus, the prostanoid EP1 receptor plays a significant role in regulating CBF and neuronal cell death. These findings suggest that pharmacologic modulation of the EP1 receptor might be a means to improve CBF and neuronal survival during ischemic stroke. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600836      PMCID: PMC2291148          DOI: 10.1002/jnr.21399

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  32 in total

Review 1.  Genetic and pharmacological analysis of prostanoid receptor function.

Authors:  S Narumiya; G A FitzGerald
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  Estrogen receptor antagonist ICI182,780 exacerbates ischemic injury in female mouse.

Authors:  M Sawada; N J Alkayed; S Goto; B J Crain; R J Traystman; A Shaivitz; R J Nelson; P D Hurn
Journal:  J Cereb Blood Flow Metab       Date:  2000-01       Impact factor: 6.200

3.  The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure.

Authors:  J L Stock; K Shinjo; J Burkhardt; M Roach; K Taniguchi; T Ishikawa; H S Kim; P J Flannery; T M Coffman; J D McNeish; L P Audoly
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

4.  Targeting PGE2 receptor subtypes rather than cyclooxygenases: a bridge over troubled water?

Authors:  Bianca Rocca
Journal:  Mol Interv       Date:  2006-04

5.  Characterization of murine vasopressor and vasodepressor prostaglandin E(2) receptors.

Authors:  Y Zhang; Y Guan; A Schneider; S Brandon; R M Breyer; M D Breyer
Journal:  Hypertension       Date:  2000-05       Impact factor: 10.190

6.  Role of prostaglandin E receptor EP1 subtype in the development of renal injury in genetically hypertensive rats.

Authors:  Takayoshi Suganami; Kiyoshi Mori; Issei Tanaka; Masashi Mukoyama; Akira Sugawara; Hisashi Makino; Seiji Muro; Kensei Yahata; Shuichi Ohuchida; Takayuki Maruyama; Shuh Narumiya; Kazuwa Nakao
Journal:  Hypertension       Date:  2003-12       Impact factor: 10.190

7.  Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction.

Authors:  Sylvain Doré; Takashi Otsuka; Toshiaki Mito; Nubuo Sugo; Tracey Hand; Liejun Wu; Patricia D Hurn; Richard J Traystman; Katrin Andreasson
Journal:  Ann Neurol       Date:  2003-08       Impact factor: 10.422

8.  EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries.

Authors:  Richard J Davis; Colin E Murdoch; Mozam Ali; Stuart Purbrick; Rivka Ravid; Gordon S Baxter; Nick Tilford; Robert L G Sheldrick; Kenneth L Clark; Robert A Coleman
Journal:  Br J Pharmacol       Date:  2004-01-26       Impact factor: 8.739

9.  Neuron-to-astrocyte signaling is central to the dynamic control of brain microcirculation.

Authors:  Micaela Zonta; María Cecilia Angulo; Sara Gobbo; Bernhard Rosengarten; Konstantin-A Hossmann; Tullio Pozzan; Giorgio Carmignoto
Journal:  Nat Neurosci       Date:  2003-01       Impact factor: 24.884

10.  Glutamate-mediated cytosolic calcium oscillations regulate a pulsatile prostaglandin release from cultured rat astrocytes.

Authors:  Micaela Zonta; Annalisa Sebelin; Sara Gobbo; Tommaso Fellin; Tullio Pozzan; Giorgio Carmignoto
Journal:  J Physiol       Date:  2003-09-18       Impact factor: 5.182

View more
  29 in total

1.  Function of prostaglandin E2 EP receptors in the acute outcome of rodent hypoxic ischemic encephalopathy.

Authors:  Hidetoshi Taniguchi; Christoph Anacker; Gabriela Beatriz Suarez-Mier; Qian Wang; Katrin Andreasson
Journal:  Neurosci Lett       Date:  2011-09-12       Impact factor: 3.046

2.  Inflammation after stroke: mechanisms and therapeutic approaches.

Authors:  Muzamil Ahmad; Steven H Graham
Journal:  Transl Stroke Res       Date:  2010-06       Impact factor: 6.829

Review 3.  Therapeutic targets in prostaglandin E2 signaling for neurologic disease.

Authors:  P J Cimino; C Dirk Keene; Richard M Breyer; Kathleen S Montine; Thomas J Montine
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

4.  Protection by vascular prostaglandin E2 signaling in hypoxic-ischemic encephalopathy.

Authors:  Hidetoshi Taniguchi; Christoph Anacker; Qian Wang; Katrin Andreasson
Journal:  Exp Neurol       Date:  2014-02-20       Impact factor: 5.330

5.  Prostaglandin signalling in cerebral ischaemia.

Authors:  Katrin Andreasson
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

6.  PGE2 EP1 receptor deletion attenuates 6-OHDA-induced Parkinsonism in mice: old switch, new target.

Authors:  Abdullah Shafique Ahmad; Takayuki Maruyama; Shuh Narumiya; Sylvain Doré
Journal:  Neurotox Res       Date:  2013-02-06       Impact factor: 3.911

7.  Selective blockade of PGE2 EP1 receptor protects brain against experimental ischemia and excitotoxicity, and hippocampal slice cultures against oxygen-glucose deprivation.

Authors:  Abdullah Shafique Ahmad; Yun Tai Yun; Muzamil Ahmad; Takayuki Maruyama; Sylvain Doré
Journal:  Neurotox Res       Date:  2008-12       Impact factor: 3.911

8.  Reversing the deleterious effects of α2-antiplasmin on tissue plasminogen activator therapy improves outcomes in experimental ischemic stroke.

Authors:  Aiilyan K Houng; Dong Wang; Guy L Reed
Journal:  Exp Neurol       Date:  2014-02-18       Impact factor: 5.330

9.  Delayed activin A administration attenuates tissue death after transient focal cerebral ischemia and is associated with decreased stress-responsive kinase activation.

Authors:  Shibani S Mukerji; Riley N Rainey; Jamie L Rhodes; Alison K Hall
Journal:  J Neurochem       Date:  2009-09-24       Impact factor: 5.372

10.  Heme-hemopexin complex attenuates neuronal cell death and stroke damage.

Authors:  Rung-chi Li; Sofiyan Saleem; Gehua Zhen; Wangsen Cao; Hean Zhuang; Jongseok Lee; Ann Smith; Fiorella Altruda; Emanuela Tolosano; Sylvain Doré
Journal:  J Cereb Blood Flow Metab       Date:  2009-03-11       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.